Oral T Peptide Modulator
Male Hypogonadism (Low Testosterone)
PreclinicalActive
Key Facts
About Acesis Biomed
Acesis BioMed is a preclinical-stage biotech targeting the multi-billion dollar male hypogonadism market with an oral peptide designed to stimulate endogenous testosterone production, offering a potential alternative to current testosterone replacement therapies (TRT). Founded on foundational IP from Dr. Vassilios Papadopoulos's research on mitochondrial cholesterol transport, the company has secured $5.8M in funding and employs a capital-efficient virtual model. Its strategy involves advancing its lead candidate to First-in-Human trials before expanding the platform into related metabolic comorbidities like type 2 diabetes and NAFLD.
View full company profile